…in over one-third of patients, especially in DLBCL treated with axicabtagene ciloleucel, while none were reported with tisagenlecleucel. Despite low mo…
Tisagenlecleucel
This drug is selected. Its supporting articles are shown below.
Articles mentioning Tisagenlecleucel
6 articles · page 1 of 1…umab) are often used in ovarian and cervical cancers. ICIs (eg, pembrolizumab) are effective in mismatch repair-deficient endometrial cancer …
…l (axi-cel), 31 (42%) tisagenlecleucel (tisa-cel), and 11 (16%) brexucabtagene autoleucel (brexi-cel). Mean V2Vt was 48±19 days (median 42) for axi-cel, …
…red in 80.8%, brexucabtagén autoleucel(Tecartus ) in 11.5%, and Tisagenlecleucel(Kymriah ) in 7.7 % of patients. The median age was 67.5 years (…
…act of Vein-to-vein Time in Patients With R/R LBCL Treated with Axicabtagene Ciloleucel. Blood Adv. 2025 Jun 10;9(11):2663–2676. doi: 10.1182/bloodadva…
…eater real-world efficacy and cytokine-associated toxicity than tisagenlecleucel (tisa-cel; CD19/4-1BB), for reasons that are poorly understood.…